Adjuvant Dabrafenib plus Trametinib in Stage III<i>BRAF</i>-Mutated MelanomaGeorgina V. Long, John M. Kirkwood, Axel Hauschild et al.|New England Journal of Medicine|2017Cited by 1.5k
Five-Year Analysis of Adjuvant Dabrafenib plus Trametinib in Stage III MelanomaReinhard Dummer, Dirk Schadendorf, Caroline Robert et al.|New England Journal of Medicine|2020Cited by 406
Longer Follow-Up Confirms Relapse-Free Survival Benefit With Adjuvant Dabrafenib Plus Trametinib in Patients With Resected <i>BRAF</i> V600–Mutant Stage III MelanomaAxel Hauschild, Georgina V. Long, Reinhard Dummer et al.|Journal of Clinical Oncology|2018Cited by 255
Final Results for Adjuvant Dabrafenib plus Trametinib in Stage III MelanomaGeorgina V. Long, Reinhard Dummer, Axel Hauschild et al.|New England Journal of Medicine|2024Cited by 123
Patient-reported outcomes in patients with resected, high-risk melanoma with BRAFV600E or BRAFV600K mutations treated with adjuvant dabrafenib plus trametinib (COMBI-AD): a randomised, placebo-controlled, phase 3 trialDirk Schadendorf, Georgina V. Long, Axel Hauschild et al.|The Lancet Oncology|2019Cited by 56